Sirona Biochem (TSX-V: SBM) presents a technical value proposition centered on the stabilization of carbohydrate molecules to improve the safety and efficacy of active ingredients. Operating through its French subsidiary TFChem, the company targets the cosmetic and pharmaceutical sectors. The deck identifies a significant market opportunity in global skin lightening, projected to reach $23.0 billion by 2020, where their lead compound claims 8 times the efficacy of Deoxyarbutin. While the presentation highlights a major partnership with Wanbang/Fosun for a diabetes drug, it lacks detailed fina…
Key takeaways
- The company operates as a parent entity in Vancouver, Canada, with a wholly owned subsidiary, TFChem, based in Cosmetic Valley, France (Slide 6).
- Sirona Biochem was founded in 2009, and TFChem was acquired in 2011 (Slide 6).
- The core technology platform specializes in the stabilization of carbohydrate molecules to overcome natural instability and complex synthesis (Slide 2 and 3).
- The global skin lightening market is a primary target, cited as growing from $15.1 billion in 2014 to a projected $23.0 billion in 2020 (Slide 5).
- Asia-Pacific is the dominant market region for skin lightening, projected to reach $14.5 billion by 2020 with a 9.3% CAGR (Slide 5).
- Sirona claims its skin lightener is hydroquinone-free and has 8 times the efficacy of Deoxyarbutin (Slide 7).
- The company has secured a commercial partnership for a diabetes drug with Wanbang/Fosun in China (Slide 7).
- The presentation lacks a management team slide, specific use of proceeds, or detailed clinical trial timelines in the provided pages.
Sirona Biochem: A Deep Dive into Carbohydrate Chemistry
The Sirona Biochem investor presentation from March 2018 serves as a technical primer for a publicly traded company (TSX-V: SBM) looking to bridge the gap between complex organic chemistry and commercial applications in skincare and medicine. The deck is structured to explain a specific scientific hurdle—carbohydrate instability—and how their proprietary platform overcomes it to create high-value ingredients.
Slide 1: Title and Identity
The cover slide establishes the company's branding and its status as a publicly traded entity on the TSX Venture Exchange under the symbol SBM. The tagline, "Advancing Chemistry. Enhancing Health," suggests a broad mandate, though the subsequent slides narrow this focus significantly toward specialized ingredients. The date, March 2018, places this deck in a specific historical context regarding their market projections.
Slide 2: Sirona’s Technology Platform
This slide introduces TFChem, a wholly owned subsidiary that serves as the R&D engine for the group. The value proposition is clearly stated: developing safer, more effective cosmetic and pharmaceutical active ingredients. The technical focus is "the stabilization of carbohydrate molecules." By leading with the subsidiary, Sirona emphasizes its specialized laboratory capabilities in France.
Slide 3: The Problem Statement - Why we do it
Slide 3 addresses the "However..." in the industry. It identifies three major drawbacks in current carbohydrate-based development: complex synthesis, instability (leading to toxicity or low efficacy), and poor pharmacological properties. This sets the stage for Sirona's solution, which claims to increase the potential of these molecules while reducing their inherent drawbacks. It is a classic problem/solution framework applied to molecular biology.
Slide 4: The Mechanism - How we do it
Using a visual representation of molecular structures, Slide 4 illustrates the stabilization process. The slide notes that "Carbohydrate molecules are unstable by nature" and shows how their technology intervenes. The stated result is improved bioavailability and selectivity. This slide is crucial for scientific due diligence, as it attempts to simplify a complex chemical process into a visual 'before and after' for investors.
Slide 5: Market Opportunity - Global Skin Lightening Market
Sirona shifts from science to economics on Slide 5. They present a bar chart showing the growth of the skin lightening market from $15.1 billion in 2014 to a projected $23.0 billion in 2020. The data, sourced from Global Industry Analysts, highlights the Asia-Pacific region as the primary driver, growing at a 9.3% CAGR. This slide justifies the company's focus on dermatology, showing a massive, growing market where their stabilized molecules could be disruptive.
Slide 6: Corporate Structure and History
This slide provides the geographic and chronological context of the company. Sirona Biochem (Parent) is based in Vancouver, while TFChem (Subsidiary) is in France's "Cosmetic Valley." The timeline shows the company was founded in 2009, with the acquisition of TFChem occurring in 2011. The use of photos of the Vancouver skyline and the TFChem facility aims to provide a sense of physical scale and institutional presence.
Slide 7: Investment Highlights
The final slide in this set summarizes the current wins and future pipeline. Key highlights include:
A skin lightener that is hydroquinone-free with 8x the efficacy of Deoxyarbutin. · A diabetes drug partnership with Wanbang/Fosun in China. · Ongoing development of an anti-wrinkle therapy with a novel mechanism of action.
This slide acts as the 'proof of concept,' showing that the technology is not just theoretical but has already resulted in a major pharmaceutical partnership and a high-performance cosmetic ingredient.
What Works in This Deck
Specific Technical Niche: Unlike many biotech decks that claim to solve 'cancer' or 'aging' broadly, Sirona focuses on a very specific chemical challenge: carbohydrate stabilization. This makes the pitch more credible to sophisticated investors who understand the difficulty of working with these molecules.
Clear Market Segmentation: Slide 5 does an excellent job of breaking down the market by geography. By highlighting the 9.3% CAGR in Asia-Pacific, they provide a clear roadmap for where their commercial efforts (or those of their partners) are likely focused.
Validation via Partnership: Mentioning Wanbang/Fosun on Slide 7 is a critical trust signal. For a micro-cap biotech company, a partnership with a large Chinese pharmaceutical group suggests that their chemistry has passed external technical audits.
What is Missing from This Deck
Management Team: The provided slides contain no information about the leadership, scientific advisory board, or the chemists at TFChem. In biotech, the pedigree of the scientific team is often as important as the IP itself.
Financials and Ask: There is no slide detailing the company's burn rate, cash position, or the specific amount of capital they are looking to raise. As a public company, some of this is in the public record, but a pitch deck should ideally summarize the 'Ask' and the 'Use of Proceeds.'
Clinical Timelines: While the deck mentions a diabetes drug and anti-wrinkle therapy, it does not specify what stage of development these are in (e.g., Pre-clinical, Phase I, Phase II). Investors need to know how far away these products are from generating significant royalty or milestone revenue.
Founder Takeaways
Visualize the 'Invisible': If your product happens at a microscopic or molecular level, use Slide 4 as a template. The use of red circles to highlight specific points of intervention in a molecular chain helps non-scientists visualize the value of the IP.
Leverage Geographic Strengths: Sirona highlights that their subsidiary is in France's "Cosmetic Valley." If your company is located in a specific hub (like Silicon Valley for tech or Boston for biotech), use that to signal your access to talent and industry ecosystems.
Focus on 'Free-From' Trends: By highlighting that their skin lightener is "hydroquinone-free," Sirona taps into a major regulatory and consumer trend. Founders should always identify the 'toxic' or 'outdated' industry standard their technology replaces.
Frequently asked questions
- What is Sirona Biochem's core technical advantage?
- According to Slide 2 and 3, Sirona Biochem specializes in the stabilization of carbohydrate molecules. Naturally, these molecules are unstable, leading to lower efficacy or toxic by-products. Sirona’s technology aims to improve bioavailability and selectivity, which translates into better safety and efficacy for both cosmetic and pharmaceutical active ingredients.
- Which markets is Sirona Biochem targeting?
- The deck explicitly details the Global Skin Lightening Market (Slide 5), projecting it to reach $23 billion by 2020. Additionally, Slide 7 mentions the development of a diabetes drug and an anti-wrinkle therapy, indicating a dual focus on high-end cosmetics (dermatology) and metabolic pharmaceuticals.
- Does Sirona Biochem have any existing commercial validation?
- Yes. Slide 7 notes that one of their technologies is currently partnered with Wanbang/Fosun in China for a diabetes drug. This provides third-party validation of their carbohydrate stabilization platform within a highly regulated pharmaceutical context.
- Where is the company located and how is it structured?
- Sirona Biochem is headquartered in Vancouver, BC, Canada. It operates through a wholly owned subsidiary, TFChem, which is located in 'Cosmetic Valley,' France. The parent company was founded in 2009, and the subsidiary was acquired in 2011 (Slide 6).
- What specific product claims does the company make regarding its cosmetic line?
- On Slide 7, the company claims to have developed a skin lightener that is hydroquinone-free. Hydroquinone is a controversial ingredient in many markets due to safety concerns. Sirona further claims their alternative has 8 times the efficacy of Deoxyarbutin.
